

Amendments to the claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (original) A method of treating a B cell hyperproliferative disorder, the method comprising:
administering to a patient an effective dose of an antibody that specifically binds to an antigen present on said B cells; and IFN- γ (gamma interferon).
2. (original) The method according to Claim 1, wherein said B cell hyperproliferative disease is a Non-Hodgkin's lymphoma.
3. (original) The method according to Claim 1, wherein said antibody is a monoclonal antibody.
4. (original) The method according to Claim 1, wherein said antibody is a humanized monoclonal antibody.
5. (original) The method according to Claim 1, wherein said antigen present on said B cells is CD20.
6. (original) The method according to Claim 1, wherein said antibody is administered at a dose of 0.001 to 30 mg/kg.
7. (original) The method according to Claim 1, wherein said IFN- γ is human IFN- γ .
8. (original) The method according to Claim 7, wherein said IFN- γ is administered at a dose of from 0.5 $\mu\text{g}/\text{m}^2$ to about 500 $\mu\text{g}/\text{m}^2$.
9. (original) The method according to Claim 7, wherein administration of said IFN- γ is initiated at least one week prior to initiation of treatment with said antibody.
10. (original) A composition comprising:
an antibody that binds to an antigen present on B cells; and gamma interferon.
11. (original) The composition of Claim 10, wherein said antibody is a monoclonal antibody.
12. (original) The composition of Claim 10, wherein said antibody is an anti-CD20 antibody.

13. The composition of Claim 10, wherein said antibody is in an amount sufficient to deliver a unit dose of about 0.001 to about 30 mg/kg.
14. (original) The composition of Claim 10, wherein said gamma interferon is human gamma interferon.
15. (original) The composition of Claim 10, wherein said gamma interferon is in an amount sufficient to deliver a unit dose of about 0.5 micrograms/m² to about 500 micrograms/m².
16. (currently amended) Use of the composition of ~~any of claims 10-15~~ claim 10 as a medicament for the treatment of a B cell proliferative disorder.
17. (original) Use according to Claim 16, wherein the disorder is a Non-Hodgkin's lymphoma.